Market Overview

UPDATE: Piper Jaffray Upgrades Myriad Genetics to Overweight on Reimbursement Strategy Confidence

Related MYGN
A Closer Look At 5 Heavily Shorted Stocks
Study Shows Prolaris Could Save Healthcare System $6B Over 10 Yrs.

Piper Jaffray raised its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Overweight and increased its price target from $28 to $35.

Piper Jaffray commented, "Management expressed a high level of confidence in their reimbursement strategy, citing multiple layers of stability and a tight range around their median rates (specifically Medicaid and managed care). Additionally, we believe Myriad's longer-term strategy to combat generic BRCAnalysis tests by expanding its panel beyond BRCA 1/2, capturing a larger percentage of heredity cancer has shades of the old, but successful, intellectual property HPV argument. Based on our diligence, management's comments and an updated DCF scenario analysis, we see the risk premium the market currently ascribes as excessive."

Myriad Genetics closed at $26.95 on Friday.

Latest Ratings for MYGN

DateFirmActionFromTo
Nov 2014Morgan StanleyInitiates Coverage onUnderperform
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters